Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 8/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.36 |
| ▸ | TUBB | P07437 | 1/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936999 | 0.92 | NPC1 (0.42) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL4073603 | 0.91 | STK17B (0.46) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL4251366 | 0.90 | KMT2A (0.39) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL4068409 | 0.87 | TYK2 (0.53) | NPC1RAB9ATYK2EGFRTUBB4A | |
| SCHEMBL4068501 | 0.86 | NPC1 (0.39) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL4075468 | 0.86 | NPC1 (0.39) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL4065036 | 0.86 | MAP3K8 (0.42) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL3927882 | 0.85 | EGFR (0.46) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL4069292 | 0.85 | EGFR (0.40) | NPC1RAB9ATYK2MEN1KMT2A | |
| SCHEMBL4077908 | 0.85 | STK17B (0.40) | NPC1RAB9ATYK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2014662-A1 | Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042913-A1 | Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | NPC1 2246/4885RAB9A 3318/4885TYK2 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.